Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission
Authors:
- S. Reyes CalzadaSCS. Reyes Calzada
- R. Martínez TomasRTR. Martínez Tomas
- M.J. Cremades RomeroMRM.J. Cremades Romero
- E. Martínez MoragónEME. Martínez Moragón
- J.J. Soler CataluñaJCJ.J. Soler Cataluña
- R. Menéndez VillanuevaRVR. Menéndez Villanueva
- 1 September 2007
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 101 (9) , 1909-1915
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired PneumoniaChest, 2005
- Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysisBMJ, 2005
- Risk factors of treatment failure in community acquired pneumonia: implications for disease outcomeThorax, 2004
- Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent AdultsClinical Infectious Diseases, 2003
- Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation studyThorax, 2003
- Addition of a Macrolide to a β‐Lactam–Based Empirical Antibiotic Regimen Is Associated with Lower In‐Hospital Mortality for Patients with Bacteremic Pneumococcal PneumoniaClinical Infectious Diseases, 2003
- Neumonía adquirida en la comunidad: utilidad de la presentación clínica para la elección del tratamiento antibióticoMedicina Clinica, 2002
- Why Don't Physicians Follow Clinical Practice Guidelines?JAMA, 1999
- Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes?The American Journal of Medicine, 1999
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997